3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
130
Squamous Cell Carcinoma of Head and Neck
76
Lung Neoplasms
49
Head and Neck Neoplasms
44
Urinary Bladder Neoplasms
43
Parkinson Disease 4, Autosomal Dominant Lewy Body
33
Nasopharyngeal Carcinoma
32
Oropharyngeal Neoplasms
31
Biliary Tract Neoplasms
30
Uterine Cervical Neoplasms
28
Cholangiocarcinoma
27
Esophageal Squamous Cell Carcinoma
25
Carcinoma
24
Neoplasms
23
Ovarian Neoplasms
22
Neoplasm Metastasis
21
Small Cell Lung Carcinoma
20
Carcinoma, Squamous Cell
19
Stomach Neoplasms
18
Colorectal Neoplasms
18
Carcinoma, Transitional Cell
17
Esophageal Neoplasms
16
Pancreatic Neoplasms
15
Mesothelioma, Malignant
15
Gallbladder Neoplasms
15
Mouth Neoplasms
13
Laryngeal Neoplasms
13
Hypopharyngeal Neoplasms
12
Recurrence
10
Medulloblastoma
10
Interventions
pembrolizumab
2
Pemetrexed
1
MRX-2843
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Cisplatin
×
1 year
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled